Mycophenolate mofetil for liver-transplanted patients
Editorial Group: Cochrane Hepato-Biliary Group
Published Online: 8 OCT 2008
Copyright © 2008 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
How to Cite
Großmann K, Langer G, Saal S, Grothues D, Wienke A. Mycophenolate mofetil for liver-transplanted patients (Protocol). Cochrane Database of Systematic Reviews 2008, Issue 4. Art. No.: CD007446. DOI: 10.1002/14651858.CD007446.
- Publication Status: New
- Published Online: 8 OCT 2008
This is the protocol for a review and there is no abstract. The objectives are as follows:
To assess benefits and harms of mycophenolate mofetil and enteric-coated mycophenolate sodium as immunosuppressive agents for liver-transplanted patients. To assess separately usefulness for achieving current (or improved) targets in anti-rejection therapy and reducing calcineurin inhibitor side-effects of mycophenolate mofetil and enteric-coated mycophenolate sodium as immunosuppressive agents for liver-transplanted patients.